Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cytotoxic T lymphocyte antigen-4 (CTLA-4) polymorphism in patients with Behçet's disease.

Düzgün N, Duman T, Keskin O, Morris Y, Tutkak H.

Clin Exp Rheumatol. 2010 Jul-Aug;28(4 Suppl 60):S100. Epub 2010 Sep 24. No abstract available.

PMID:
20868585
2.

CTLA-4 gene variants are not associated with Behçet's disease or its clinical manifestations.

Touma Z, Hamdan A, Shamseddeen W, Nasr J, Makhoul N, Zalloua PA, Arayssi T.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4 Suppl 50):S132. No abstract available.

PMID:
19026137
3.

CTLA-4 +49A/G polymorphism is associated with Behçet's disease in a Tunisian population.

Ben Dhifallah I, Chelbi H, Braham A, Hamzaoui K, Houman MH.

Tissue Antigens. 2009 Mar;73(3):213-7. doi: 10.1111/j.1399-0039.2008.01186.x.

PMID:
19254250
4.

CTLA-4 polymorphisms are not associated with ocular inflammatory disease.

Bye L, Modi N, Stanford MR, Kondeatis E, Vaughan R, Fortune F, Kanawati C, Ben-Chetrit E, Ghabra M, Murray PI, Wallace GR.

Tissue Antigens. 2008 Jul;72(1):49-53. doi: 10.1111/j.1399-0039.2008.01062.x. Epub 2008 May 20.

PMID:
18498289
5.

CTLA-4 gene 49A/G polymorphism in Turkish patients with Behçet's disease.

Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O.

Clin Exp Dermatol. 2005 Sep;30(5):546-50.

PMID:
16045690
6.

Lack of association between CTLA-4 +49A/G and -318C/T polymorphisms and Behçet's disease risk: a meta-analysis.

Zhang YJ, Xu WD, Duan ZH, Liu SS, Pan HF, Ye DQ.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S46-50. Epub 2012 Sep 25. Review.

PMID:
23010350
7.

No association of CTLA-4 polymorphisms with susceptibility to Behçet disease.

Du L, Yang P, Hou S, Zhou H, Kijlstra A.

Br J Ophthalmol. 2009 Oct;93(10):1378-81. doi: 10.1136/bjo.2008.156919. Epub 2009 Jun 30. Review.

PMID:
19570770
8.

CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease.

Park KS, Baek JA, Do JE, Bang D, Lee ES.

Tissue Antigens. 2009 Sep;74(3):222-7. doi: 10.1111/j.1399-0039.2009.01303.x. Epub 2009 Jun 25.

PMID:
19563524
9.

Increased peripheral blood gamma delta+ T cells and natural killer cells in Behçet's disease.

Suzuki Y, Hoshi K, Matsuda T, Mizushima Y.

J Rheumatol. 1992 Apr;19(4):588-92.

PMID:
1534375
10.

The role of CTLA-4 exon-1 49 A/G polymorphism and soluble CTLA-4 protein level in egyptian patients with Behçet's disease.

Abdel Galil SM, Hagrass HA.

Biomed Res Int. 2014;2014:513915. doi: 10.1155/2014/513915. Epub 2014 Jun 2.

11.

CTLA-4 polymorphisms and susceptibility to Behcet's disease: a meta-analysis.

Lee YH, Song GG.

Mol Biol Rep. 2012 Sep;39(9):9041-5. doi: 10.1007/s11033-012-1775-9. Epub 2012 Jun 22.

PMID:
22722994
12.

Increased risk of human leukocyte antigen-G gene variants in Behçet's disease.

Park KS, Nam JH, Lee ES, Choi JS, Bang D, Lee S.

Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S126-7. No abstract available. Erratum in: Clin Exp Rheumatol. 2007 May-Jun;25(3):507-8.

PMID:
17067446
13.

Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma.

Kämmerer PW, Toyoshima T, Schöder F, Kämmerer P, Kuhr K, Brieger J, Al-Nawas B.

Oral Oncol. 2010 Jul;46(7):543-8. doi: 10.1016/j.oraloncology.2010.03.025.

PMID:
20435510
14.

Haplotypes of the endothelial protein C receptor gene and Behçet's disease.

Navarro S, Bonet E, Medina P, Martos L, Ricart JM, Vayá A, Todolí J, Fontcuberta J, Estellés A, España F.

Thromb Res. 2012 Apr;129(4):459-64. doi: 10.1016/j.thromres.2011.07.032. Epub 2011 Aug 17.

PMID:
21851971
15.

No association of PTPN22 polymorphisms with susceptibility to ocular Behcet's disease in two Chinese Han populations.

Zhang Q, Hou S, Jiang Z, Du L, Li F, Xiao X, Kijlstra A, Yang P.

PLoS One. 2012;7(3):e31230. doi: 10.1371/journal.pone.0031230. Epub 2012 Mar 2.

16.

Clinical features of Japanese patients with Behçet's disease and MICA polymorphism.

Nishiyama M, Takahashi M, Manaka K, Suzuki S, Saito M, Nakae K.

Jpn J Ophthalmol. 2005 Sep-Oct;49(5):424-6. No abstract available.

PMID:
16187048
17.

Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity.

Accardo-Palumbo A, Giardina AR, Ciccia F, Ferrante A, Principato A, Impastato R, Giardina E, Triolo G.

Arthritis Res Ther. 2010;12(3):R109. doi: 10.1186/ar3043. Epub 2010 Jun 3.

18.

Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behçet's disease.

Duymaz-Tozkir J, Gül A, Uyar FA, Ozbek U, Saruhan-Direskeneli G.

Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S15-8.

PMID:
14727453
19.

Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease.

Gunesacar R, Erken E, Bozkurt B, Ozer HT, Dinkci S, Erken EG, Ozbalkan Z.

Int J Immunogenet. 2007 Feb;34(1):45-9.

PMID:
17284227
20.

Immunohistological studies in neuro-Behçet's disease.

Hirohata S, Arai H, Matsumoto T.

Adv Exp Med Biol. 2003;528:385-7. No abstract available.

PMID:
12918730

Supplemental Content

Support Center